Contact this trialFirst, we need to learn more about you.
NMDA receptor antagonist
Emraclidine for Schizophrenia
Recruiting0 awardsPhase 2
Miami Springs, Florida
This trial is testing a new medication called Emraclidine, given in two different doses daily. It aims to help people with schizophrenia who are having severe symptom flare-ups. The medication works by targeting specific parts of the brain to reduce symptoms like hallucinations and delusions.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.